PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HYPOXIA-INDUCED PULMONARY ARTERIAL HYPERTENSION COMPRISING ROSIGLITAZONE AS AN ACTIVE INGREDIENT

摘要

A pharmaceutical composition comprising rosiglitazone is provided to inhibit growth and mobility of pulmonary smooth muscle cells and pulmonary revascularization by reducing expressions of ET-1(endothelin-1) and VEGF(vascular endothelial growth factor) and increasing expression of PPARgamma(peroxisome proliferator-activated receptor) in pulmonary tissue, so that it is useful for preventing or treating hypoxia-induced pulmonary arterial hypertension. A pharmaceutical composition for preventing or treating hypoxia-induced pulmonary arterial hypertension comprises rosiglitazone as an effective ingredient, further comprises a pharmaceutically acceptable carrier and a pharmaceutically acceptable supplement selected from solvent, disintegrant, sweetener, binder, coating agent, blowing agent, lubricant and flavoring agent, and is formulated as solution, suspension, emulsion, pill, capsule, granule or tablet, wherein the daily dosage of the composition is 0.5-5mg/day.